Virica Biotech

📣 BIO Europe is around the corner and we will be there! Meet with our Chief Strategy Officer Ella Korets-Smith to learn how we deliver unparalleled success to cell and gene therapy (CGT) manufacturers and developers. Virica’s cell enhancers, called Viral Sensitizers (VSEᵀᴹ), and Design of Experiments (DoE) powered workflows unlock: ✔ Rapid viral vector production optimization. ✔ Robust increase in viral vector yield and quality. ✔ Significant reduction in long-term manufacturing costs. 💡 Looking to drive up CGT manufacturing productivity and drive down COGS? 🤝 Connect with us through partnering: https://hubs.la/Q02VX5vv0 Or through our website: https://hubs.la/Q02VX3N80 Curious about our technology? Here’s a brief overview: https://hubs.la/Q02VX69-0 #innovation #biomanufacturing #BIOEurope

Last week, Virica exhibited at Ontario Centre of Innovation's AGM! Cell and gene therapies (CGT) have offered curative solutions and transformed health care. However, it remains unaffordable and inaccessible to patients in need. Virica is here to change that! Our cell enhancers, called Viral Sensitizers (VSEᵀᴹ), remove the barriers to manufacturing CGTs at scale by increasing manufacturing productivity and reducing costs. Virica is proud to be a flagship company in the Ontario biomanufacturing sector and we are grateful for the support from Ontario Centre of Innovation through our journey. Visit our website to learn how we help scale life-saving cell and gene therapies: https://hubs.la/Q02V-dbk0 #OCI #M2M #innovation #biotechnology

Yesterday, our expert Oliver Varette showcased how Virica leverages Design of Experiments (DoE) to rapidly optimize LV and AAV production at #EGSCT2024. 💡 Design of Experiments (DoE) unlocks the design space-driving efficiencies through speed, cost-effectiveness, optimization throughput and predictive power. Now imagine what you can achieve by combining the statistical power of DoE with High-Throughput Virology! At Virica, we do just that! Want to learn more about how DoE has been a game-changer for Virica? Join us for our upcoming webinar on Optimizing AAV Production with Design of Experiments (DoE), hosted by BioInsights: 📅 Date: November 20, 2024 ⏰ Time: 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET 👉 Register now: https://hubs.la/Q02V9hr70 At ESGCT? Don’t miss our other posters: https://lnkd.in/dSp-YVKR Check out our latest data: https://lnkd.in/dfHmmMGt #innovation #biomanufacturing #AAV

Navigating the fast-paced cell and gene therapy landscape? 💡 Stay ahead of the curve with our curated news on viral vectors in cell & gene therapy October 2024 edition covering Q3 2024. #biomanufacturing #innovation #cgtreads

Innovation meets efficiency in AAV production! 📣 Join Virica Biotech and REITHERA for a collaborative presentation on Thursday, the 24th at 11 AM at Booth B14/16 at #ESGCT2024 #AAV #GeneTherapy #Biotech #LifeSciences #ViricaBiotech #Innovation

📢Don't miss our upcoming webinar where we partner with Culture Biosciences and explore how thier cloud connected buoreactors and our DoE workflows can accelerate scale up of AAV manufacturing. Link to register below👉

Cell and Gene Therapy (CGT) manufacturing is undeniably complex, with many variables! 💡 Design of Experiments (DoE) unlocks the design space-driving efficiencies through speed, cost-effectiveness, optimization throughput and predictive power. This means evaluating complex interactions between the various manufacturing inputs to optimize for desired outcomes—functional titer, impurity, genomic titer, quality, and even cost reduction—all at once! 👉 Check out our latest read on DoE: https://hubs.la/Q02V8HBP0 We’ve teamed up to show how Virica’s Viral Sensitizer (VSEᵀᴹ) platform and Culture Biosciences cloud-based bioreactors can improve productivity, shorten timelines, and ensure more efficient AAV production scale-up. Join us for our upcoming webinar on Optimizing AAV Production with Design of Experiments (DoE), hosted by BioInsights 📅 Date: November 20, 2024 ⏰ Time: 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET Webinar topics include: 🔹 Identifying key challenges that impact AAV production 🔹 Virica’s High-Throughput Virology (HTVᵀᴹ) to identify optimal cell-enhancing molecules 🔹 How Culture’s cloud-connected bioreactor platform enables rapid evaluation of production parameters with transparent data transfer 🔹 Real-world data comparing the efficiency and yield improvements between DoE-based compound identification and traditional non-DoE methods Register now: https://hubs.la/Q02V9hr70 #AAV #GeneTherapy #Biotech #Webinar #DoE #Biomanufacturing

Boosting AAV Productivity through Innovation! Join Virica Biotech and REITHERA on Thursday, 24th at 11 AM at Booth B14/16 at #ESGCT2024 to discover the latest insights on increasing AAV production. 🚀. Learn how; 🔹 Virica’s Viral Sensitizer (VSE™) platform enhances viral yields by reducing cellular defenses during AAV production. 🔹 ReiThera’s proprietary clonal cell line, ReiCell–AAVx, optimized for high-density suspension growth. 🔹 ReiThera uses Virica’s cell enhancers in combination with their ReiCell–AAVx cell line with a presentation of their latest data. Together, these innovations have the potential to enhance AAV titers across multiple serotypes. Don’t miss this opportunity to learn how combining these technologies can drive your gene therapy projects forward! #AAV #GeneTherapy #Biotech #LifeSciences #ViricaBiotech #Innovation

📣 We are going to be in Barcelona attending World Vaccine Congress Europe! Our expert Oliver Varette is attending and he’d love to chat! Are you looking to drive up viral vaccine manufacturing yield and drive down manufacturing COGS? Drop by our poster presentation: ✔Development and Scale-up Validation of Small Molecule Viral Sensitizers for Increased Vaccine Manufacturing Yields. Learn about how leveraging our Viral Sensitizers (VSEᵀᴹ) and Design of Experiments (DoE) powered workflows unlock: ✔ Rapid viral vector production optimization. ✔ Robust increase in viral vector yield and quality. ✔ Significant reduction in long-term manufacturing COGS. Connect with us through our website: https://lnkd.in/dZc63P3J Want a quick overview of our technology? https://lnkd.in/gu2m3RcX #biomanufacturing #innovation #WVC

📣 We’re thrilled to announce a new collaboration project with eXmoor Pharma, funded by a joint UK-Canada government initiative. This project aims to enhance the manufacturing of adeno-associated vectors (AAVs) crucial for gene therapies, ultimately reducing costs and improving the accessibility of life-saving therapies. 🔬 Key Highlights: ✔ Leveraging Virica’s Viral Sensitizers (VSE™) formulations to boost AAV yields. ✔ Expertise from eXmoor in optimizing the manufacture of vectors and scaling up to commercial levels. The collaboration underscores a shared commitment between the UK and Canada to leverage innovative technologies to tackle future healthcare challenges. 🔗 Link to Full PR: https://lnkd.in/d84tr5zZ 🔗 Learn more about us: eXmoor Pharma: https://lnkd.in/eARjGFwK Virica Biotech: https://lnkd.in/e3zvChi #biomanufactruing #innovation #AAV #UK #Canada